Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation

被引：3
|
作者：
Edwards, David K. [1 ]
Javidi-Sharifi, Nathalie [1 ]
Rofelty, Angela [2 ]
Rosenfeld, Claire [3 ]
Roth-Carter, Riley [3 ]
Tardi, Paul [4 ]
Mayer, Lawrence [4 ]
Tyner, Jeffrey W. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA
[4] Jazz Pharmaceut, Vancouver, BC, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5124.5124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5124
引用
收藏
页数：4
相关论文
共 50 条
  • [1] CPX-351 works synergistically in combination with FLT3 inhibitors against AML with FLT3-ITD
    Edwards, David K.
    Javidi-Sharifi, Nathalie
    Rofelty, Angela
    Gordon, Max
    Roth-Carter, Riley
    Tardi, Paul
    Mayer, Lawrence
    Tyner, Jeffrey W.
    CANCER RESEARCH, 2017, 77
  • [2] CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation
    Gordon, Max J.
    Tardi, Paul
    Loriaux, Marc M.
    Spurgeon, Stephen E.
    Traer, Elie
    Kovacsovics, Tibor
    Mayer, Lawrence D.
    Tyner, Jeffrey W.
    LEUKEMIA RESEARCH, 2017, 53 : 39 - 49
  • [3] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jian-kang
    Wilson, Kelli
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2015, 126 (23)
  • [4] Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation
    Heng, Hao
    Zhi, Yanle
    Yuan, Haoliang
    Wang, Zhijie
    Li, Hongmei
    Wang, Shuxian
    Tian, Jieyi
    Liu, Haichun
    Chen, Yadong
    Lu, Tao
    Ran, Ting
    Lu, Shuai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 195 - 206
  • [5] FLT3-ITD Mutation in Relation to FLT3 Expression in Pediatric AML: A Prospective Study from India
    Sharawat, Surender Kumar
    Bakhshi, Radhika
    Vishnubhatla, Sreenivas
    Gupta, Ritu
    Bakhshi, Sameer
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 31 (02) : 131 - 137
  • [6] Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells
    Zhao, Linxiang
    Zuo, Shuwei
    Xing, Kun
    Yue, Xiaoshuang
    Zhang, Huimin
    Zhang, Jingyi
    Waxman, Samuel
    Jing, Yongkui
    CANCER RESEARCH, 2024, 84 (06)
  • [7] CPX-351 cytotoxicity against fresh AML blasts is increased for FLT3-ITD+ cells and correlates with drug uptake and clinical outcomes
    Gordon, Max
    Tardi, Paul
    Mayer, Lawrence D.
    Tyner, Jeffrey
    CANCER RESEARCH, 2016, 76
  • [8] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
    Dan Xu
    Yishan Chen
    Ying Yang
    Zhao Yin
    Changfen Huang
    Qiang Wang
    Ling Jiang
    Xuejie Jiang
    Changxin Yin
    Qifa Liu
    Guopan Yu
    Journal of Translational Medicine, 20
  • [9] The effect of FLT3 gene expression in senescence and telomere length regulation in AML cells with FLT3-ITD mutation
    Hong, Jing Siou
    Yen, Jui Hung
    Wu, Chia Ling
    Chen, Pei Yi
    CANCER SCIENCE, 2025, 116 : 256 - 256
  • [10] Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
    Xu, Dan
    Chen, Yishan
    Yang, Ying
    Yin, Zhao
    Huang, Changfen
    Wang, Qiang
    Jiang, Ling
    Jiang, Xuejie
    Yin, Changxin
    Liu, Qifa
    Yu, Guopan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
12345